TNF Therapy May Protect The Heart
Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2013 Nov 28.
TNF inhibitor therapy may provide cardioprotective effects that extend beyond their clinical effects on joint disease, according to data presented at recent conferences. In a cohort of 1829 patients without pre-existing coronary artery disease, risk of incident coronary artery disease was reduced by 46% in those using TNF inhibitors compared with nonusers.77 Risk was reduced by 76% in patients who used TNF inhibitors for more than 24 months. In a multivariate regression model that included more than 109,400 patients, cumulative use of TNF inhibitors for 1, 2, and 3 years was associated with a risk reduction in cardiovascular events of 24%, 42%, and 56%, respectively, compared with not using TNF inhibitors. Cardiovascular disease as a comorbidity in patients with RA will be discussed in more detail in POSSIBLE LINKChapter 5.1, Monitoring and Treatment of Comorbid Conditions.